MedTrace Logo

Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders

NCT06068829 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-10-05

No results posted yet for this study

Summary

To compare the safety and efficacy of Inebilizumab and Rituximab in neuromyelitis optica spectrum disorders (NMOSD) patients.

Conditions

  • Neuromyelitis Optica Spectrum Disorders

Interventions

DRUG

Inebilizumab

Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inebilizumab was given after IVMP.

DRUG

Rituximab(RTX)

RTX: 500mg IV on Day 1 and Day15. The first dose of RTX was given after IVMP.

Sponsors & Collaborators

  • Feng Jinzhou

    lead OTHER

Principal Investigators

  • Jinzhou Feng, Ph.D · First Affiliated Hospital of Chongqing Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-20
Primary Completion
2024-06-30
Completion
2025-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06068829 on ClinicalTrials.gov